The court’s order tracks the joint motion language precisely, dismissing ‘all claims of infringement that Plaintiff raised or could have raised’ — the broadest possible with-prejudice scope, extinguishing not just pleaded claims but any infringement theory Mobile Health might have advanced. The inclusion of Citizen Watch Company of America, Inc. (the U.S. subsidiary) as a named party to the motion, alongside the Japanese parent, suggests the release was structured to cover both entities. The own-costs provision is commercially neutral and typical of negotiated exits at this litigation stage.

Any R&D or product team commercialising a touchscreen smartwatch, fitness wearable, or connected health monitoring device in the US market should evaluate exposure to US11468984B2. The claims were never adjudicated on the merits in this case, meaning the patent carries no court-imposed limitation on scope. Products featuring real-time health data monitoring, step or activity tracking, or biometric display on a touchscreen wearable interface are the most commercially proximate risk categories.

PatSnap Eureka’s FTO Search Agent can map US11468984B2’s independent claims against your product specification, identify prior art that could support an IPR or ex parte reexamination strategy, and surface any continuation or divisional applications that may extend the patent family’s coverage. Given that this case closed without claim construction, a proactive FTO and landscape analysis is the most defensible posture for wearable health tech product teams entering or expanding in the US market.